



VIA REGISTERED POST AND EMAIL

Attention: General Counsel- MENA

Hikma Pharmaceuticals LLC

Bayader Wadi El Seer, Industrial Area, Saleem Bin Al Hareth Street, Building No. 21, P.O. Box 182400,

Amman, 11118, Jordan

Email: zeluteibi@hikma.com

Date: 29 August 2025

Re: Notice of Termination for the Molnupiravir Licence Agreement

Dear General Counsel,

We refer to the licence agreement between the Medicines Patent Pool ("**MPP**") and Hikma Pharmaceuticals LLC ("**Licensee**") dated 10/01/2022 concerning patents and know-how pertaining to molnupiravir ("**Licence Agreement**").

MPP is entitled to terminate this Licence Agreement with immediate effect pursuant to Section 10.3(c) of the Licence Agreement, as the Licensee failed to fulfill its obligation under Section 3.3, specifically the requirement to submit a complete file for WHO Prequalification or any SRA approval within thirty-six (36) months from the Effective Date for any existing formulation of the Products.

As such, please accept this letter as formal notice that, without any further written notice, MPP hereby terminates the Licence Agreement with effect from 29 August 2025.

This Licence Agreement is hereby terminated without prejudice to the surviving provisions of the Licence Agreement, including sections 3A, 6.1(e), 7.3, 8, 10.5, 11, and 12.

Sincerely,

For and on behalf of Medicines
Patent Pool

A handwritten signature in black ink, appearing to be "Chan Park", is written over a horizontal line.

Name: Chan Park

Title: General Counsel

Date: 29 August 2025